<DOC>
	<DOCNO>NCT01889212</DOCNO>
	<brief_summary>New treatment strategy develop lung cancer target Epidermal Growth Factor Receptor ( EGFR ) . Patients activate mutation EGFR high responds rate treatment treat EGFR inhibitor first line treatment . Some wild type patient well respond selection patient difficult . Erlotinib label 11C used new PET tracer . Accumulation tracer ( 11C-erlotinib ) tumor show promising result selection responder . The investigator want conduct large clinical study evaluate accumulation tracer pre-treatment 11C-erlotinib PET/CT predict respond erlotinib .</brief_summary>
	<brief_title>Imaging With 11C-erlotinib PET/CT Identify Responders Erlotinib Treatment NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Lung Cancer patient nonsmall cell histology stage IV disease candidate erlotinib treatment first/ second/ third line treatment pregnancy severe dyspnoea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>